VTRS on XNAS, Health Care, Viatris Inc., job postings
Measures activity, not value. Not investment advice.
Shares rose 93% in a year while the company posted a 12-month net loss of $607.8M.
WatchTwelve-month revenue up 4.3% to $14.7B, but quarterly revenue slipped 0.3%
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.7B, net loss $325.3M.
31 Dec 2021RevenueNet incomeNet losstallest bar $4.3B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$3.7B
-$325.3M
30 Jun 2026
$3.8B
-$118.8M
31 Mar 2026
$3.5B
$176.4M
31 Dec 2025
$3.7B
–
30 Sep 2025
$3.8B
-$128.2M
30 Jun 2025
$3.6B
-$4.6M
31 Mar 2025
$3.3B
-$3.0B
31 Dec 2024
$3.5B
–
30 Sep 2024
$3.8B
$94.8M
30 Jun 2024
$3.8B
-$326.4M
31 Mar 2024
$3.7B
$113.9M
31 Dec 2023
$3.8B
–
30 Sep 2023
$3.9B
$331.6M
30 Jun 2023
$3.9B
$264.0M
31 Mar 2023
$3.7B
$224.7M
31 Dec 2022
$3.9B
–
30 Sep 2022
$4.1B
$354.3M
30 Jun 2022
$4.1B
$313.9M
31 Mar 2022
$4.2B
$399.2M
31 Dec 2021
$4.3B
–
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$14.7B
$14.1B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+4.3%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$607.8M
-$3.7B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.53
-$3.09
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
35.3%
36.0%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-0.0%
-18.8%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-4.1%
-26.1%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-4.2%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$2.1B
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$1.8B
$975.3M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$13.3B
$14.4B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$11.5B
$13.5B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.97
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$11.94
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.5
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
2.3
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.6
2.0
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
2.4%
2.5%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+2.2%
1,026 13F filers vs 1,004
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
89%
1.0B shares held by 13F filers (30 Sep 2026) of 1.1B outstanding (2 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.1%
35.2M shares sold short (30 Oct 2026) of 1.1B outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.0
35.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-7.1%
37.9M shares sold short in the report before, 35.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
46%
46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
30K
reported for the year to 31 Dec 2025
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-0.3%
$3.7B vs $3.8B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-1.3%
$85.7M vs $86.8M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$2.0M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
35
35 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.8×
35 articles in the last 7 days; its usual week has 4.
Price $19.63 on 20 Nov 2026, +93% over 12 months (12-month range $10.19 to $21.06)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $1.1M in the last 12 months (the 12 months before: $684K).Revenue per quarter. Revenue $3.7B in the latest quarter, -0.3% on a year earlier.Capital spending per quarter. Capital spending $85.7M in the latest quarter, -1.3% on a year earlier.Institutional holders (13F filers). 1,026 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: -$0.0 published in the last 12 months (none in the 12 months before).Lobbying spend. Lobbying spend: $2.0M published in the last 12 months, -19% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $4.3B, +20% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $4.2B, -5.4% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $4.1B, -10% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $4.1B, -10% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $3.9B, -11% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $3.7B, -11% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $3.9B, -4.8% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $3.9B, -3.3% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $3.8B, -1.0% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $3.7B, -1.8% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $3.8B, -3.1% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3.8B, -4.8% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $3.5B, -8.1% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $3.3B, -11% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $3.6B, -5.6% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $3.8B, +0.2% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $3.7B, +5.0% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $3.5B, +8.1% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.8B, +4.9% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.7B, -0.3% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $197.4M, +69% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $64.5M, +30% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $83.9M, -6.0% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $103.9M, -14% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $153.7M, -22% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $47.8M, -26% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $67.8M, -19% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $95.9M, -7.7% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $165.5M, +7.7% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $49.8M, +4.2% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $58.8M, -13% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $77.0M, -20% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $140.4M, -15% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $42.6M, -14% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $52.9M, -10% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $86.8M, +13% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $196.5M, +40% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $39.9M, -6.3% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $52.8M, -0.2% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $85.7M, -1.3% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 930; public on 14 Feb 2022
31 Mar 2022 report: 945; public on 16 May 2022
30 Jun 2022 report: 925; public on 15 Aug 2022
30 Sep 2022 report: 877; public on 14 Nov 2022
31 Dec 2022 report: 908; public on 14 Feb 2023
31 Mar 2023 report: 903; public on 15 May 2023
30 Jun 2023 report: 881; public on 14 Aug 2023
30 Sep 2023 report: 866; public on 14 Nov 2023
31 Dec 2023 report: 925; public on 14 Feb 2024
31 Mar 2024 report: 940; public on 15 May 2024
30 Jun 2024 report: 934; public on 14 Aug 2024
30 Sep 2024 report: 932; public on 14 Nov 2024
31 Dec 2024 report: 970; public on 14 Feb 2025
31 Mar 2025 report: 947; public on 15 May 2025
30 Jun 2025 report: 918; public on 14 Aug 2025
30 Sep 2025 report: 917; public on 14 Nov 2025
31 Dec 2025 report: 960; public on 17 Feb 2026
31 Mar 2026 report: 990; public on 15 May 2026
30 Jun 2026 report: 1,004; public on 14 Aug 2026
30 Sep 2026 report: 1,026; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2022: -$2.5 published
Month from 1 Dec 2025: -$0.0 published
Month from 1 Apr 2026: -$0.0 published
Lobbying spend
Quarter from 1 Jan 2022: $630K published
Quarter from 1 Apr 2022: $670K published
Quarter from 1 Jul 2022: $680K published
Quarter from 1 Oct 2022: $830K published
Quarter from 1 Jan 2023: $650K published
Quarter from 1 Apr 2023: $690K published
Quarter from 1 Jul 2023: $780K published
Quarter from 1 Oct 2023: $720K published
Quarter from 1 Jan 2024: $620K published
Quarter from 1 Apr 2024: $630K published
Quarter from 1 Jul 2024: $770K published
Quarter from 1 Oct 2024: $640K published
Quarter from 1 Jan 2025: $510K published
Quarter from 1 Apr 2025: $650K published
Quarter from 1 Jul 2025: $650K published
Quarter from 1 Oct 2025: $700K published
Quarter from 1 Jan 2026: $550K published
Quarter from 1 Apr 2026: $550K published
Quarter from 1 Jul 2026: $420K published
Quarter from 1 Oct 2026: $510K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 80 (21 Aug 2017), 15% below its normal reading of 94.
Reported lobbying spend: $510K in Q3 2026, $420K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Feb 2025
New
S-3 Groupfor Viatris (Mylan, Inc)
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug TestingHealth issues
Issues related to e-labeling.; Issues related to drug pricing; issues related to pharmaceutical supply chain; issues related to modernization of prescribing information for physicians and pharmacists; Improved Access to Affordable Medications Act, S. 1120; Increasing Transparency in Generic Drug Applications, S.775 and HR 3839; P; Issues related to Inter Partes Review and patent policy generally; Preserve Access to Affordable Generics and Biosimilars Act, S.142; Affordable Prescriptions for Patients Act, S. 150 Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023,; Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).Pharmacy, Health issues, Copyright/patents, Budget
Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs. H.R.1503, Prescription Information Modernizati; Issues related to modernizing access to prescribing information.Health issues, Budget
spent $197.4M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year.
Same quarter last year: $116.9M; its normal quarter is $49.5M.
See the evidence
This period
$197.4M (the quarter ended 31 Dec 2021)
Normal quarter (median of 7 earlier)
$49.5M
Typical spread (median absolute deviation)
$11.3M
How far from its usual level
+8.8
Same quarter last year
$116.9M
History used
640 days
the quarter ended 31 Dec 20217 earlier quartersnormal: $49.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $121.0M on capital projects in the quarter ended 30 Sep 2021, 3.2× the same quarter last year.
Same quarter last year: $38.2M; its normal quarter is $47.0M.
See the evidence
This period
$121.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 6 earlier)
$47.0M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
+8.1
Same quarter last year
$38.2M
History used
548 days
the quarter ended 30 Sep 20216 earlier quartersnormal: $47.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $4.4B for the quarter ended 31 Mar 2021, 1.7× the same quarter last year.
Same quarter last year: $2.6B; its normal quarter is $0.
See the evidence
This period
$4.4B (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+4400.1
Same quarter last year
$2.6B
History used
640 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.
Not listed: 116 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001792044
Ticker
VTRS
Domain
viatris.com
Employer name
Meda Pharmaceuticals, Inc., Mylan Technologies Inc. (2 unverified)
Fein
03-0336833 (1 unverified)
Hq location
PA|CANONSBURG|15317 (1 unverified)
Lobbying client
mylan laboratories, viatris, viatris mylan
Name
Abbex AB, Acton Pharmaceuticals, Inc, Aculys Pharma, Inc, Agila Australasia Pty Ltd and 245 more
Uei
NEYRLCN7HME7, TZY5BKQHCF21
Wikidata
Q101983981
Wikipedia
Viatris
DOL H-1B labor condition applications and PERM certifications2 data points9 Mar 2026 to 9 Mar 2026
Federal lobbying disclosures (LDA)35 records, 276 data points30 Jun 1999 to 30 Sep 2026
SEC Form 13F institutional holdings9 records, 216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)112 records7 May 2020 to 17 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)551 data points31 Dec 2017 to 2 Nov 2026
SEC Form 4 insider transactions33 records, 120 data points18 Dec 2020 to 26 Jun 2026
FINRA short interest (twice monthly)425 data points30 Nov 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3020 data points17 Nov 2020 to 20 Nov 2026
USASpending.gov federal awards12 data points31 Oct 2022 to 14 Jan 2026
WARN layoff notices (state labor agencies)2 records, 6 data points26 Sep 2016 to 24 Aug 2017
Wikipedia pageviews2456 data points11 Dec 2019 to 20 Nov 2026